{
  "profile_url": "https://www.moffitt.org/research-science/researchers/rami-komrokji/",
  "last_updated": "2025-11-21T22:50:26.502112",
  "researcher_id": "4734",
  "degrees": [
    "MD"
  ],
  "title": "",
  "primary_program": "malignant hematology",
  "research_program": "molecular medicine",
  "overview": "Our clinical trials focus on novel therapies for myelodysplastic syndromes, myeloproliferative neoplasms and acute myeloid leukemia. Our large myeloid institution research database serves as robust Real-world dataset and provides sets for clinical and translational research.",
  "research_interests": [
    "Dr. Komrokji\u2019s research interests are in Phase I and II Clinical Trials, and in outcome research in hematologic malignancies with focus on myeloid neoplasms. His clinical interests are Myelodysplastic syndromes (MDS), Acute Leukemias, and Myeloproliferative neoplasms.\n  *"
  ],
  "associations": [
    "Malignant Hematology",
    "Experimental Therapeutics Program",
    "Molecular Medicine Program"
  ],
  "education": [
    {
      "type": "Medical School",
      "institution": "Jordan University School of Medicine"
    },
    {
      "type": "Internship",
      "institution": "Case Western University, St. Vincent Program",
      "position": "Intern"
    },
    {
      "type": "Residency",
      "institution": "Case Western University, St. Vincent Program",
      "position": "Intern",
      "specialty": "al Medicine"
    },
    {
      "type": "Fellowship",
      "institution": "Strong Memorial Hospital, University of Rochester",
      "specialty": "Hematology/Oncology"
    },
    {
      "type": "Board Certification",
      "institution": "Internal Medicine",
      "certification": "Hematology"
    }
  ],
  "publications": [
    {
      "title": "The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non-JAK Inhibitor Therapies",
      "pubmed_id": "41030319",
      "pmc_id": "PMC12477285",
      "year": "2025",
      "publication_date": "2025 Sep",
      "authors": "Reynolds SB, Komrokji R, Kuykendall AT",
      "journal": "Blood Lymphat Cancer"
    },
    {
      "title": "Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression",
      "pubmed_id": "40254502",
      "year": "2025",
      "publication_date": "2025 Sep",
      "authors": "Aguirre LE, Ball S, Jain A, Ali NA, Sallman DA, Kuykendall A, Sweet K, Lancet JE, Padron E, Komrokji RS",
      "journal": "Clin Lymphoma Myeloma Leuk"
    },
    {
      "title": "Transfusion Independence Corresponds With Survival in Patients With Lower-Risk Myelodysplastic Syndrome: Real-World Evidence From United States Insurance Claims",
      "pubmed_id": "40410022",
      "year": "2025",
      "publication_date": "2025 Oct",
      "authors": "Komrokji RS, Supina D, Navada S, Potluri R, Tyagi R, Werwath T, Xie Z, Padron E, Sallman DA",
      "journal": "Clin Lymphoma Myeloma Leuk"
    },
    {
      "title": "Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms",
      "pubmed_id": "40059041",
      "year": "2025",
      "publication_date": "2025 Oct",
      "authors": "Gisriel SD, Aakash F, Bennett JM, Hasserjian RP, Loghavi S, DeZern AE, Santini V, Savona MR, Brunner AM, Buckstein R, Wei AH, Della Porta MG, Komrokji RS, Borate UM, Sekeres MA, Platzbecker U, Fenaux P, Roboz GJ, van de Loosdrecht A, Zeidan AM, Xu ML",
      "journal": "Arch Pathol Lab Med"
    },
    {
      "title": "XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies",
      "pubmed_id": "40737597",
      "year": "2025",
      "publication_date": "2025 Oct",
      "authors": "Kruer TL, Quintana-Gonzalez A, Newman HL, Ferrall-Fairbanks MC, Zhang L, McLemore AF, Neupane S, Yang Q, Ben-Crentsil NA, Balasis ME, Letson CT, Komrokji RS, Chaudhry S, Totiger TM, Traina JA, Figueroa ME, Ryder CB, Cluzeau T, Taylor J, Sallman DA, Padron E",
      "journal": "Blood"
    },
    {
      "title": "Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm",
      "pubmed_id": "40453136",
      "pmc_id": "PMC12067887",
      "year": "2025",
      "publication_date": "2025 May",
      "authors": "Xie Z, Al Ali N, Zhang L, Papenhausen P, Volpe VO, Chan O, Kuykendall A, Yun S, Walker A, Sweet K, Lancet JE, Padron E, Sallman DA, Komrokji RS",
      "journal": "Blood Neoplasia"
    },
    {
      "title": "How I treat higher-risk MDS",
      "pubmed_id": "39808802",
      "year": "2025",
      "publication_date": "2025 May",
      "authors": "Mina A, Komrokji RS",
      "journal": "Blood"
    },
    {
      "title": "A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome",
      "pubmed_id": "40153010",
      "pmc_id": "PMC12031784",
      "year": "2025",
      "publication_date": "2025 Mar",
      "authors": "Garcia-Manero G, Gaddh M, Platzbecker U, Lindsley RC, Larson SM, Chevassut T, Fenaux P, Komrokji R, Lyons R, Al-Kali A, Jiang Y, Bothos J, Townsley DM, Zeidan AM",
      "journal": "Ann Hematol"
    },
    {
      "title": "Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study",
      "pubmed_id": "39535901",
      "year": "2025",
      "publication_date": "2025 Mar",
      "authors": "Sekeres MA, Santini V, D\u00edez-Campelo M, Komrokji RS, Fenaux P, Savona MR, Madanat YF, Valc\u00e1rcel-Ferreiras D, Oliva EN, Regnault A, Creel K, Sengupta N, Dougherty S, Shah S, Sun L, Wan Y, Navada S, Zeidan AM, Platzbecker U",
      "journal": "Leuk Lymphoma"
    },
    {
      "title": "Advancing drug development in myelodysplastic syndromes",
      "pubmed_id": "39786387",
      "pmc_id": "PMC11914162",
      "year": "2025",
      "publication_date": "2025 Mar",
      "authors": "Mina A, McGraw KL, Cunningham L, Kim N, Jen EY, Calvo KR, Ehrlich LA, Aplan PD, Garcia-Manero G, Foran JM, Garcia JS, Zeidan AM, DeZern AE, Komrokji RS, Sekeres MA, Scott BL, Buckstein RJ, Tinsley-Vance S, Verma A, Wroblewski T, Pavletic SZ, Norsworthy KJ",
      "journal": "Blood Adv"
    }
  ],
  "grants": [
    {
      "description": "Title: Use Machine Learning to Identify Novel Image-Based Markers That Can Distinguish Between ICUS, CCUS, and MDS and Aid in the Prediction of Disease Evolution, Survival, and Genetic Evolution in Patients with Pre-MDS Condition and MDS  \nAward Number:   \nSponsor: THE EDWARD P. EVANS FOUNDATION  \nEl N. (PD/PI), Komrokji, R. (Co-PD/PI)",
      "title": "Use Machine Learning to Identify Novel Image-Based Markers That Can Distinguish Between ICUS, CCUS, and MDS and Aid in the Prediction of Disease Evolution, Survival, and Genetic Evolution in Patients with Pre-MDS Condition and MDS",
      "award_number": "",
      "sponsor": "THE EDWARD P. EVANS FOUNDATION  \nEl N. (PD/PI),",
      "investigators": [
        {
          "name": "Komrokji, R.",
          "role": "Co-PD/PI"
        }
      ]
    },
    {
      "description": "Title: Myeloproliferative Neoplasms-Research Consortium  \nAward Number: 2P01CA108671-15  \nSponsor: National Cancer Institute (NCI)  \nKomrokji, R. (PD/PI)",
      "title": "Myeloproliferative Neoplasms-Research Consortium",
      "award_number": "2P01CA108671-15",
      "sponsor": "National Cancer Institute (NCI)",
      "source": "NCI",
      "investigators": [
        {
          "name": "Komrokji, R.",
          "role": "PD/PI"
        }
      ]
    }
  ],
  "participating_trials": [
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-21247/",
      "trial_id": "21247",
      "title": "A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK)-Inhibitor",
      "condition": "Malignant Hematology",
      "intervention": "Imetelstat (GRN163L)",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-21405/",
      "trial_id": "21405",
      "title": "Phase 2, Single Arm Study of Luspatercept for the Treatment of Anemia in lower Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN)",
      "condition": "Malignant Hematology",
      "intervention": "ACE-536 (Luspatercept); Luspatercept ()",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-23208/",
      "trial_id": "23208",
      "title": "A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoietin-stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The \"ELEMENT-MDS\" Trial",
      "condition": "Malignant Hematology",
      "intervention": "ACE-536 (Luspatercept); Epoetin Alfa (erythropoietin); Luspatercept ()",
      "status": "Open"
    }
  ],
  "lab_page_url": "",
  "google_scholar_url": "",
  "photo_url": "https://www.moffitt.org/globalassets/images/researchers_bio/KomrokjiRami_4734.jpg",
  "contact": {
    "contact_url": "https://eforms.moffitt.org/ContactResearchersForm?PERID=4734"
  },
  "content_hash": "494aa7e477418e20a9488c2910da4898d74102b0563eff83e6377d949dcf68a1",
  "researcher_name": "rami komrokji",
  "department": ""
}